As Congress considers drug price reforms, Merck, Lilly and Takeda execs warn of dire consequences

As Congress reconvenes this month to resolve a $3.5 trillion budget package, Democrats are focused on enacting sweeping legislation that would allow the government to negotiate prices for prescription drugs. On Wednesday, Merck’s executive chairman and former CEO Ken Frazier warned of dire consequences from such a move. “The proposals that we’re seeing from Congress will devastate this industry,” Frazier said during a virtual press conference hosted by lobbying organization PhRMA.

Read the source article at Pharma News
2021-09-08 16:23:41